Trial Profile

A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary) ; Diphenhydramine; Diphenhydramine; Methylprednisolone; Paracetamol
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Acronyms MUSETTE
Sponsors Roche

Most Recent Events

18 Mar 2026 This trial has been completed in Germany, Greece, Belgium and Denmark according to CTIS.
02 Apr 2025 According to Roche media release, data from this study will be presented at an upcoming medical meeting.
02 Apr 2025 Primary endpoint has not been met. (Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12))

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com